UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
-
Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
-
Cellectar Biosciences (CLRB) Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
-
Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
-
Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering
-
Cellectar Biosciences (CLRB) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock, Warrants
-
Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering
-
Roth Capital Transfers Coverage on Cellectar Biosciences (CLRB) at Buy
-
Roth Capital Reiterates $11 PT on Cellectar Biosciences (CLRB) Following Sept. 13 Initiation
-
Roth Capital Starts Cellectar Biosciences (CLRB) at Buy
-
Pre-Open Movers 07/09: (ACIA) (SOLO) (CLRB) (LITE) (FNSR) (LNN) (more...)
-
NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Secures $10M Through RDO Sale, Private Placement
-
Cellectar Biosciences Announces Closing of $10.0 Million Financing
-
Cellectar Biosciences (CLRB) Offerings Result in Total Gross Proceeds of $10M
-
Cellectar Biosciences Announces $10.0 Million Financing
-
Cellectar Biosciences to Present at the 28th Annual Roth Capital Conference

